A clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Our immuno oncology product candidates include a clinical-stage monoclonal antibody and a portfolio of bispecific antibodies.
Lead Underwriter
Citigroup Global Markets Inc, Credit Suisse Securities (USA) LLC, Stifel Nicolaus & Company, Incorporated
